Sai Life Sciences SAILIFE
Small-molecule CRDMO serving innovator pharma and biotech from discovery to commercial supply
Mapped in 1 theme: Pharmaceuticals.
Where Sai Life Sciences sits in the supply chain
Sai Life Sciences appears in 1 supply-chain layer in one theme, Pharmaceuticals.
Pharmaceuticals › CDMO & contract research
Direct supplierOther companies in this layer
Revenue and profit
| ₹ Cr | FY24 | FY25 | FY26 |
|---|---|---|---|
| Revenue | 1,465 | 1,695 | 2,192 |
| Net profit | 83 | 170 | 349 |
Latest-year revenue ₹2,192 Cr (FY26, company-wide). Wider screens show FY22 onwards.
Strengths
- Fast growth: FY26 profit ₹349 Cr vs ₹6 Cr in FY22
- Well placed for BIOSECURE-driven vendor diversification
Risks
- Very rich valuation (see the figures)
- Biotech funding sensitivity and customer concentration
Common questions
What does Sai Life Sciences do?
Small-molecule CRDMO serving innovator pharma and biotech from discovery to commercial supply.
Where does Sai Life Sciences sit in the supply chain?
Sai Life Sciences (NSE: SAILIFE) is mapped in 1 supply-chain layer: CDMO & contract research (Pharmaceuticals).
Who are Sai Life Sciences' peers?
In the CDMO & contract research layer of Pharmaceuticals: Divi's Laboratories, Syngene International, Anthem Biosciences, Cohance Lifesciences, Piramal Pharma, Laurus Labs and 4 more.
What is Sai Life Sciences' market cap and valuation?
As of 30 Oct 2026: market cap ₹33,109 Cr, P/E 90.0x, ROCE 19.6%, ROE 15.4%, dividend yield 0%.